Indian drug makers are now tapping their feet to become the world’s largest drug market as the US market reduce the healthcare costs for American consumers. It is done by the data exclusivity period to 7 years from 12 years for patented biotech medicines. Kiran Mazumdar Shaw’s Biocon, Dr Reddy’s Laboratories and Wockhardt are competing to launch their biosimilar drug in the US as the global market for biosimilars is estimated at $55-60 billion and estimated to swell to $300 billion by 2020. The lowered healthcare cost will provide incentives to new drug developers for future research. The proposal is welcomed and is detrimental for innovation. The Generic Pharmaceutical Association (GPhA) said, “There is no question that a 12-year exclusivity period would provide unwarranted monopolies for brand biopharmaceuticals, which would delay the savings that could result from the earlier introduction of biogenerics.” On the other hand,harmaceutical Research and Manufacturers of America (PhRMA) representing large US drug makers would seriously threaten innovative companies’ ability to fund research on future treatments and cures. But both GPhA and PhRMA have strongly opposed the proposal to ban cozy settlements between patent holders and generic drug makers. This may deprive consumers to early access to low-cost medicines. It is a good one time opportunity for local drug makers as an earning opportunity to save legal costs associated with challenging a patent.